• Mangoceuticals closed a $500,000 registered direct offering with a U.S.-based private investment firm.
• Units were priced at $0.75, each with one common share and one warrant, representing a 74% premium to $0.43.
• Financing adds working capital at the parent level; warrant exercises could increase dilution.
• Separately, MangoRx IP Holdings secured $2.5 million in strategic investment commitments for 25% of the subsidiary; $1.75 million received.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610091601PRIMZONEFULLFEED9843213) on October 09, 2026, and is solely responsible for the information contained therein.